Investigational drug · Phase 3
Firmonertinib
Also called: AST2818
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
17
Any phase or sponsor naming "Firmonertinib"
First trial start
2024
Nov 19, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Firmonertinib", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Non-Small-Cell Lung Cancer
- Metastatic Non-Small-Cell Lung Cancer
- Advanced Non-Small-Cell Lung Cancer
- EGFR P-Loop and Alpha C-Helix Compressing
- EGFR PACC
- EGFR Uncommon Mutations
- Non-Small Cell Lung Cancer With EGFR Mutation
- NSCLC
- Adjuvant Treatment
- EGFR
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Firmonertinib" as an intervention, largest first.
ArriVent BioPharma, Inc.Industry
NCT07185997 · 480 participants (planned) · Start Dec 17, 2025 · Primary completion Feb 2029
Drug: Firmonertinib; EGFR-TKI inhibitor based on investigator's choice · For: Non-Small-Cell Lung Cancer; Metastatic Non-Small-Cell Lung Cancer; Advanced Non-Small-Cell Lung Cancer and 3 more
Sites: Fullerton, California; Los Angeles, California; Orange, California · 141 sites in all
- Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)Pivotal-lookingActive, not recruiting
ArriVent BioPharma, Inc.Industry
NCT05607550 · 398 participants · Start Jun 1, 2023 · Primary completion Oct 6, 2026
Drug: furmonertinib 240 mg oral, daily; furmonertinib 160 mg oral, daily and 1 more · For: Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations
Sites: Daphne, Alabama; Yuma, Arizona; Fayetteville, Arkansas · 208 sites in all
Allist Pharmaceuticals, Inc.Industry
NCT06970639 · 380 participants (planned) · Start Sep 26, 2024 · Primary completion Mar 2029
Drug: Furmonertinib Mesilate Tablets; Carboplatin Injection and 3 more · For: NSCLC Patients With Brain Metastasis
Sites: Guangdong, China
Allist Pharmaceuticals, Inc.Industry
NCT07010419 · 338 participants (planned) · Start May 28, 2025 · Primary completion Oct 31, 2028
Drug: Firmonertinib; Placebo · For: NSCLC; Adjuvant Treatment
Sites: Beijing, China; Guangdong, China
- Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q MutationPivotal-lookingRecruiting
Allist Pharmaceuticals, Inc.Industry
NCT06956001 · 300 participants (planned) · Start Nov 19, 2024 · Primary completion Dec 2027
Drug: Firmonertinib Mesilate Tablets; Pemetrexed Disodium for Injection and 2 more · For: EGFR; NSCLC (Advanced Non-small Cell Lung Cancer)
Sites: Beijing, China; Shandong, China
- Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System MetastasisCompleted
Beijing Tiantan HospitalAcademic, hospital or other
NCT07239102 · 300 participants · Start Jan 1, 2020 · Primary completion May 1, 2025
Drug: Firmonertinib · For: EGFR Positive Non-small Cell Lung Cancer; Central Nervous System Metastasis; Leptomeningeal Metastasis
Sites: Beijing, China
Anhui Provincial Cancer HospitalAcademic, hospital or other
NCT07661173 · 154 participants (planned) · Start Jun 6, 2026 · Primary completion Mar 6, 2029
Drug: Firmonertinib; Firmonertinib/pemetrexed/Carboplatin and 1 more · For: Non Small Cell Lung Cancer
Sites: Hefei, China
Qiming WangGovernment (non-federal)
NCT06971406 · 100 participants (planned) · Start May 15, 2025 · Primary completion Jan 1, 2027
Drug: Combination therapy prospective cohort · For: Non Small Cell Lung Cancer; EGFR Mutation; Leptomeningeal Metastases and 1 more
- High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLCNot yet recruiting
Peking University Cancer Hospital & InstituteAcademic, hospital or other
NCT07182708 · 62 participants (planned) · Start Oct 1, 2025 · Primary completion Dec 30, 2029
Drug: Firmonertinib Mesilate Tablets; Bevacizumab injection · For: NSCLC (Non-small Cell Lung Cancer); EGFR Activating Mutation; Resectable Lung Non-Small Cell Carcinoma
Sites: Beijing, China
Peking University Cancer Hospital & InstituteAcademic, hospital or other
NCT07622706 · 60 participants (planned) · Start Sep 3, 2026 · Primary completion Dec 30, 2029
Drug: Firmonertinib 80mg qd oral for 8 weeks.; Firmonertinib 160mg qd oral for 8 weeks. and 2 more · For: NSCLC; EGFR Positive Non-small Cell Lung Cancer; Neoadjuvant Therapy
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape.
Monaca F, Randulfe I, Heymach JV, et al. · J Clin Oncol 2026
- Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations.
Le X, Wang J, Yu Y, et al. · Cancer Cell 2026
- One structural class, one treatment? Firmonertinib in PACC-mutant NSCLC.
Huang DD, Yang JC · Cancer Cell 2026
- Firmonertinib 160mg in EGFR-Mutated NSCLC with Brain Metastases After EGFR-TKI Resistance (iFORCE): Clinical Outcomes and Mechanistic Insights.
You M, Xie T, Wu L, et al. · Neuro Oncol 2026
- Furmonertinib demonstrated efficacy in a case of advanced pancreatic cancer with a 19-exon deletion mutation and wild-type KRAS: a case report and literature review.
Du F, Liu D, Jiao A, et al. · Front Pharmacol 2026
- Osalmid inhibits lung adenocarcinoma progression and enhances EGFR-TKI responses: a preclinical and translational study.
Wu L, Xu Z, Jiang W, et al. · Transl Lung Cancer Res 2026
Also in development for Non-Small-Cell Lung Cancer
- AndamertinibPLB1004Phase 38 trials
Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer
- VebreltinibPLB1001Phase 36 trials
Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, Glioblastoma, Non-Small Cell Lung Cancer
- CAB-AXL-ADCBA3011Phase 22 trials
BioAtla, Inc. · Non-Small-Cell Lung Cancer, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
- ImzokitugBMS-986340Phase 22 trials
Bristol Myers Squibb · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Cervical Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.